PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693)
Primary Target and PDB code of Protein-Drug complex
ANTINEOPLASTIC TREATMENT OF PEDIATRIC NEUROFIBROMAS (PN) MITOGEN-ACTIVATED PROTEIN KINASE KINASES 1 AND 2 INHIBITOR N-DESMETHYL SELUMETINIB REPRESENTS LESS THAN 10% OF SELUMETINIB LEVELS IN HUMAN PLASMA BUT IS APPROXIMATELY 3 TO 5 TIMES MORE POTENT CONTRIBUTING TO ABOUT 21% TO 35% OF THE OVERALL PHARMACOLOGIC ACTIVITY
-
MEK1 MEK2
Dual specificity mitogen-activated protein kinase kinase 1 INHIBITOR Q02750 (MP2K1_HUMAN)
PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693)
Primary Target and PDB code of Protein-Drug complex